Clinical trial
Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From…
NCT00406315 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00406315 |
|---|---|
| Title | Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone |
| Official title | A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | ziprasidone |
| Enrollment | 255 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Dec 4, 2006 |
| Last update posted | Mar 29, 2021 |
| Countries | Brazil, Germany, Greece, Spain, Turkey (Türkiye), United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: